1️⃣ FDA just approved the first hearing-loss gene therapy
FDA approved Otarmeni on April 23 for OTOF-related severe-to-profound hearing loss after a 61-day review under its national priority voucher program; 80% of 20 evaluable patients improved hearing in the pivotal study.
💡 Why it matters
FDA moved a dual-vector gene therapy in two months. That shortens timeline risk for rare-disease gene therapy programs nearing market.
☕ Coffee talk
If a dual-vector gene therapy can clear FDA in 61 days, what else stops being “too early to model”?
2️⃣ CMS and FDA just collapsed the device coverage lag
CMS and FDA launched RAPID on April 23 so eligible Breakthrough Devices can get a proposed Medicare coverage decision the day they win FDA authorization, with coverage possible in about two months.
💡 Why it matters
Reimbursement risk now moves into trial design. If Medicare evidence is aligned before approval, device adoption gets easier to underwrite.
☕ Coffee talk
Same-day NCD proposal and TCET paused. Which device theses are now execution bets rather than policy bets?
3️⃣ EMA just gave Sanofi a real nrSPMS opening
EMA’s CHMP recommended Cenrifki on April 24 for non-relapsing secondary progressive multiple sclerosis, backing a drug that delayed 6-month confirmed disability progression by 31% in Sanofi’s Phase 3 HERCULES study.
💡 Why it matters
MS money has long chased relapse control while progression without relapses had no real path. A real EU opening changes that market.
☕ Coffee talk
If Europe clears a drug for progression without relapses, how long does the MS market keep selling relapse control?